CVKD
Cadrenal·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Stock Price Surged Significantly
Ample Liquidity
Gap Up
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CVKD
Cadrenal Therapeutics, Inc.
A biopharmaceutical company for the prevention of cardiogenic systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation
822 A1A North, Suite 306, Ponte Vedra, Florida 32082
--
Cadrenal Therapeutics, Inc., was registered as a Delaware corporation on January 25, 2022. The company is developing the company's drug candidate ticafalin for unmet need in anticoagulation therapy. Ticafalin is an advanced novel oral and reversible anticoagulant (blood thinner) for the prevention of heart attack, stroke, and death from blood clots in patients with rare cardiovascular diseases that require chronic anticoagulation.
Company Financials
EPS
CVKD has released its 2025 Q3 earnings. EPS was reported at -1.31, versus the expected -1.55, beating expectations. The chart below visualizes how CVKD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
